SAFit2 ameliorates paclitaxel-induced neuropathic pain by reducing spinal gliosis and elevating pro-resolving lipid mediators
Open Access
- 24 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-21
Abstract
Background: Chemotherapy-induced neuropathic pain (CIPN) describes a pathological pain state that occurs dose-dependently as a side effect and can limit or even impede an effective cancer therapy. Unfortunately, current treatment possibilities for CIPN are remarkably confined and mostly inadequate as CIPN therapeutics themselves consist of low effectiveness and may induce severe side effects, pointing out CIPN as pathological entity with an emerging need for novel treatment targets. Here, we investigated whether the novel and highly specific FKBP51 inhibitor SAFit2 reduces paclitaxel-induced neuropathic pain. Methods: In this study, we used a well-established multiple low-dose paclitaxel model to investigate analgesic and anti-inflammatory properties of SAFit2. For this purpose, the behavior of the mice was recorded over 14 days and the mouse tissue was then analyzed using biochemical methods. Results: Here, we show that SAFit2 is capable to reduce paclitaxel-induced mechanical hypersensitivity in mice. In addition, we detected that SAFit2 shifts lipid levels in nervous tissue toward an anti-inflammatory and pro-resolving lipid profile that counteracts peripheral sensitization after paclitaxel treatment. Furthermore, SAFit2 reduced the activation of astrocytes and microglia in the spinal cord as well as the levels of pain-mediating chemokines. Its treatment also increased anti-inflammatory cytokines levels in neuronal tissues, ultimately leading to a resolution of neuroinflammation. Conclusions: In summary, SAFit2 shows antihyperalgesic properties as it ameliorates paclitaxel-induced neuropathic pain by reducing peripheral sensitization and resolving neuroinflammation. Therefore, we consider SAFit2 as a potential novel drug candidate for the treatment of paclitaxel-induced neuropathic pain.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB1039 A09, SFB1039 Z01, 445757098)
- Bundesministerium für Forschung, Technologie und Raumfahrt (51TaValP)
- Fraunhofer-Institut für Translationale Medizin und Pharmakologie (Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Foundation Project Neuropathic Pain)
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
This publication has 76 references indexed in Scilit:
- Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve traumaAnnals of Neurology, 2013
- Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota MetabolismPLOS ONE, 2013
- Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic painBrain, 2013
- FKBP51 and FKBP52 in signaling and diseaseTrends in Endocrinology & Metabolism, 2011
- DHA inhibits ER Ca2+ release and ER stress in astrocytes following in vitro ischemiaJournal of Neurochemistry, 2011
- Emerging roles of resolvins in the resolution of inflammation and painTrends in Neurosciences, 2011
- Chemokine CCL2 modulation of neuronal excitability and synaptic transmission in rat hippocampal slicesJournal of Neurochemistry, 2010
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001